AstraZeneca said on Monday its experimental precision drug developed with Japan's Daiichi Sankyo did not significantly ...

AstraZeneca and Daiichi Sankyo’s TROP2-directed antibody-drug conjugate (ADC) has again failed to improve overall survival ...

AstraZeneca said on Monday its experimental precision drug developed with Daiichi Sankyo did not significantly improve ...

Parnassus Investments, an investment management company, released the “Parnassus Growth Equity Fund” second quarter 2024 ...

It said the drug did not 'achieve statistical significance' in terms of the survival rates of those suffering from breast ...

Reuters.com is your online source for the latest news stories and current events, ensuring our readers up to date with any ...

Datopotamab deruxtecan is a TROP2-directed DXd ADC engineered by Daiichi Sankyo and co-developed by AstraZeneca and Daiichi Sankyo. The data pertaining to this compound will be presented at an ...

A new AstraZeneca drug has failed to extend significantly the lives of breast cancer patients in a blow to the company’s ambitions to hit an $80bn revenue target by 2030. Datopotamab deruxtecan ...

A new dose-finding study supported the potential of the carbonic anhydrase inhibitor as an alternative to CPAP machines.

Vicebio has raised $100m in a Series B funding round led by TCGX. Credit: MargJohnsonVA via Shutterstock. UK-based startup ...

AstraZeneca's cancer drug, datopotamab deruxtecan, failed to meet targets in a Phase 3 trial, clouding the possibility of approval from the U.S. Food and Drug Administration. Shares were down 1.2% at ...

AstraZeneca's breast cancer drug datopotamab deruxtecan didn't show a statistical significance in overall survival compared with chemotherapy, results showed at a phase three trial.